Skip to main content

NIH: Gene therapy didn't cause death

An experimental gene therapy treatment did not cause a patient's linkurl:death;https://www.the-scientist.com/news/display/53453/ earlier this year, according to a federal advisory committee. The National Institutes of Health's Recombinant DNA Advisory Committee announced the findings this morning (Dec. 3) and made recommendations to alter the design of the study, which was cleared by the US Food and Drug Administration to linkurl:resume;https://www.the-scientist.com/blog/display/53886/ last week.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
An experimental gene therapy treatment did not cause a patient's linkurl:death;https://www.the-scientist.com/news/display/53453/ earlier this year, according to a federal advisory committee. The National Institutes of Health's Recombinant DNA Advisory Committee announced the findings this morning (Dec. 3) and made recommendations to alter the design of the study, which was cleared by the US Food and Drug Administration to linkurl:resume;https://www.the-scientist.com/blog/display/53886/ last week. Building upon preliminary findings, which __The Scientist__ linkurl:reported;https://www.the-scientist.com/news/display/53593/ in September, the RAC presented additional data fingering a systemic linkurl:fungal infection;https://www.the-scientist.com/blog/display/53589/ and massive retroperitoneal hemorrhage as the primary causes of 36-year-old Jolee Mohr's death in July. RAC chairman Howard Federoff suggested that the trial should boost hematological monitoring of patients and said that the treatment should not be administered to patients who show physiological signs of infection prior to treatment, or those who have histories of opportunistic infection. Federoff also said that informed consent forms in this study should be revised to mention Mohr's death and to discuss the importance of autopsy should an adverse event occur again. Mohr died on July 24th, three weeks after she had received her second dose of an experimental treatment for rheumatoid arthritis. The treatment was delivered via an adeno-associated viral vector, and was part of a phase I/II clinical trial conducted by Seattle-based drug company Targeted Genetics. A RAC team, consisting of NIH scientists, representatives from Targeted Genetics and researchers from FDA and the University of Chicago (where Mohr was taken just prior to her death), has been investigating Mohr's death since July. In today's meeting, RAC executive secretary Jacqueline Corrigan-Curay presented additional data gleaned from autopsy, hematological, and PCR analysis that point to histoplasmosis, an aggressive fungal infection, and a large abdominal hemorrhage that resulted in organ failure as the main causes of Mohr's death. Corrigan-Curay said that tests could not identify significant quantities of the experimental vector, the therapeutic gene, or the transgene product outside the site of Mohr's injection (her right knee). This suggests that the gene therapy was not involved in the organ failure that ultimately killed Mohr. Though investigators deemed it unlikely, the RAC investigation could not rule out that Mohr's death was due to an immune response her body mounted against the treatment. Federoff said that more data should be collected, especially relating to Mohr's use of immunosuppressant arthritis drugs at the time of the experimental treatment. "The potential role of immunosuppressant in altering the risks to subjects enrolled in gene transfer trials needs to be carefully considered," he said. Federoff also revisited a questioned raised by Mohr's widower, Robb Mohr, during September's RAC meeting. At that meeting, Federoff said, Mohr asked if his wife would have died had she not been involved in the Targeted Genetics trial. "Despite every effort that was conceivable," Federoff said, "we are still missing key pieces of information" about the state of Mohr's immune system preceding her death and its reaction to the experimental gene transfer treatment. "At this point in time," he said, "we can't answer his question."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo